Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Equity Average (2016 - 2025)

Historic Equity Average for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to $2.7 million.

  • NovaBay Pharmaceuticals' Equity Average rose 107670.33% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 107670.33%. This contributed to the annual value of $1.6 million for FY2024, which is 7703.35% down from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Equity Average stood at $2.7 million, which was up 107670.33% from $5.2 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Equity Average high stood at $16.7 million for Q2 2022, and its period low was -$228500.0 during Q2 2024.
  • In the last 5 years, NovaBay Pharmaceuticals' Equity Average had a median value of $8.7 million in 2023 and averaged $7.6 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Equity Average soared by 363413.46% in 2021 and then tumbled by 10261.85% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Equity Average (Quarter) stood at $9.8 million in 2021, then increased by 24.59% to $12.2 million in 2022, then plummeted by 57.47% to $5.2 million in 2023, then crashed by 90.89% to $471500.0 in 2024, then surged by 467.76% to $2.7 million in 2025.
  • Its Equity Average stands at $2.7 million for Q3 2025, versus $5.2 million for Q2 2025 and $3.0 million for Q1 2025.